PULM — Pulmatrix, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1574235 ·
Last close
$1.34
Market Cap
$4.89M
52W High
$3.18
52W Low
$1.16
ADV30
27,026
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -1,292,000 | -1,172,000 | 4,496,000 | 3,324,000 | 905,000 |
| Dec 2025 | 0 | — | -908,000 | -928,000 | 4,139,000 | 4,088,000 | 329,000 |
| Sep 2025 | 0 | — | -866,000 | -877,000 | 4,982,000 | 4,794,000 | 249,000 |
| Jun 2025 | 0 | — | -1,548,000 | -1,549,000 | 6,152,000 | 5,825,000 | 548,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-5,433,000
Investing CF
$0
Financing CF
$0
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.87
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-302,318,000
Inventory
—
Receivables
$16,000
ST Investments
—
EBIT TTM
$-5,169,000
Pretax Income TTM
$-5,162,000
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -5,169,000 | -5,162,000 | 4,139,000 | 329,000 | — | -5,433,000 |
| Dec 2024 | 7,806,000 | -7,145,000 | -9,559,000 | 9,943,000 | 996,000 | — | -10,716,000 |
| Dec 2023 | 7,298,000 | -14,740,000 | -14,121,000 | 33,958,000 | 15,963,000 | — | -15,985,000 |
| Dec 2022 | 6,071,000 | -18,947,000 | -18,836,000 | 40,953,000 | 9,844,000 | — | -19,356,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.50
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CTTH | CTT PHARMACEUTICAL HOLDINGS, INC. | $4.85M | $0.08 | — |
| DRMA | Dermata Therapeutics, Inc. | $4.95M | $1.23 | — |
| ADIL | ADIAL PHARMACEUTICALS, INC. | $4.80M | $2.24 | — |
| RNAZ | Transcode Therapeutics, Inc. | $5.12M | $5.39 | — |
| MTNB | Matinas BioPharma Holdings, Inc. | $4.66M | $0.73 | — |
News headlines (Yahoo Finance, 1h cache)
Pulmatrix Announces First Quarter 2026 Financial Results
2026-05-15 12:20 · Yahoo
Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger
2026-04-21 12:00 · Yahoo
Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan
2026-03-26 12:00 · Yahoo
Wave crashes on obesity drug update; Kodiak’s reboot pays dividends
2026-03-26 10:46 · Yahoo
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction
2026-03-03 13:23 · Yahoo
Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities
2026-03-02 13:00 · Yahoo
Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results
2026-02-26 13:05 · Yahoo
Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives
2025-12-18 13:05 · Yahoo
Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets
2025-10-16 12:05 · Yahoo
Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets
2025-08-06 12:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.